Real-life experience of efficacy and safety of bilastine in the refractory cases of chronic spontaneous urticaria and its effect on the quality of life of patients
Introduction: Second-generation H1-antihistamines (SGAHs) are the mainstay of treatment of chronic spontaneous urticaria (CSU). Bilastine, newer non-sedating SGAHs, was recently introduced in India after the approval of the Drugs Controller General of India. There is a paucity of evidence about the...
Αποθηκεύτηκε σε:
Κύριοι συγγραφείς: | Abhishek De (Συγγραφέας), Kiran Godse (Συγγραφέας), Dhiraj Dhoot (Συγγραφέας), Aarti Sarda (Συγγραφέας) |
---|---|
Μορφή: | Βιβλίο |
Έκδοση: |
Wolters Kluwer Medknow Publications,
2021-01-01T00:00:00Z.
|
Θέματα: | |
Διαθέσιμο Online: | Connect to this object online. |
Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Bilastine in Refractory Chronic Spontaneous Urticaria: Disease Control and Cytokine Modulation in an Open-label Prospective Study
από: Abhishek De, κ.ά.
Έκδοση: (2024) -
Comparative clinical assessment of updosing of bilastine and combination of levocetirizine and hydroxyzine in chronic spontaneous urticaria
από: Bela Shah, κ.ά.
Έκδοση: (2022) -
Experience with bilastine in the management of urticaria: Original Real-world cases of Bilastine In Treatment (ORBIT) in Asia
από: Wai Kwong Cheong, κ.ά.
Έκδοση: (2022) -
Real-World Efficacy and Safety of Oral Tofacitinib in Patients with Refractory Moderate to Severe Atopic Dermatitis: A Multicenter Retrospective Study
από: Sandipan Dhar, κ.ά.
Έκδοση: (2024) -
Comparative efficacy of bilastine, levocetirizine and desloratadine updosing in chronic urticaria
από: Staevska MT
Έκδοση: (2016)